Liquidia Corporation (NASDAQ: LQDA) today announced Michael Kaseta
has been appointed Chief Financial Officer (CFO), effective
immediately. He succeeds Steve Bariahtaris who has served as
Liquidia’s interim CFO since August 2020. Mr. Bariahtaris has
agreed to provide assistance to the Company for a short period of
time to support a smooth transition.
“After an extensive search and thorough review of many
outstanding candidates, it is with great pleasure that, today, we
welcome Mike Kaseta to the Liquidia team,” said Neal Fowler, Chief
Executive Officer at Liquidia. “I am confident that Mike’s
financial expertise, business acumen, relevant therapeutic
knowledge, as well as his extensive leadership across companies at
varying stages in their lifecycle, make him a well-suited leader to
support the execution of our plan and position us for growth as a
fully integrated company that now includes RareGen and LIQ861 on
the horizon, if approved.”
Mr. Fowler added, “In the four months since being appointed
interim CFO, Steve’s contributions to our business were both
significant and exceptional, leaving us with a stronger balance
sheet and a high-performing finance function. We are very grateful
for his unwavering commitment to our business during this time, as
well as his close involvement in selecting and onboarding Mike as
his successor.”
Mr. Kaseta joins Liquidia with an extensive background in
corporate finance, business strategy and the commercialization of
biopharma products. Prior to Liquidia, Mr. Kaseta served as the
Chief Financial Officer at Aerami Therapeutics, a private biotech
company focused on the development of improved therapies for the
treatment of severe respiratory diseases, including pulmonary
arterial hypertension (PAH). Previously, Mr. Kaseta served as the
Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq:
ARLZ) and spent eleven years at Sanofi in a variety of financial
roles, culminating in the Chief Financial Officer at Sanofi SA for
North America Global Services and the North America Pharmaceutical
Region. In this role he managed a $10 billion business covering
several product launches and over one hundred products across eight
therapeutic areas.
“I am thrilled to join Liquidia at such a pivotal time for the
company and to have the opportunity to contribute to its mission to
bring much needed treatment options to the PAH community,” said
Michael Kaseta, Chief Financial Officer at Liquidia Corporation. “I
look very forward to developing a close and productive working
relationship with the Liquidia leadership team and to advance our
near and long-term strategies for value creation and growth.”
Mr. Kaseta holds a BBA in accounting from James Madison
University and is a CPA (inactive) licensed in the state of New
Jersey.
About Liquidia
CorporationLiquidia Corporation operates through
the company’s subsidiaries, Liquidia Technologies, Inc. and
RareGen, LLC (RareGen). The Company, through Liquidia Technologies,
Inc., is a late-stage clinical biopharmaceutical company focused on
the development and commercialization of products using its PRINT
technology. It is focused on developing two product candidates:
LIQ861, an inhaled dry powder formulation of treprostinil for the
treatment of pulmonary arterial hypertension (PAH), and LIQ865, an
injectable, sustained-release formulation of bupivacaine for the
management of local post-operative pain for three to five days
after a procedure. RareGen provides commercialization for rare
disease pharmaceutical products, such as Sandoz Inc.’s generic
treprostinil for PAH.
Liquidia Corporation is headquartered in Research
Triangle Park, NC. For more information, please
visit www.liquidia.com.
Cautionary Statements Regarding Forward-Looking
StatementsThis press release may include forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. All statements contained in this press release
other than statements of historical facts, including statements
regarding our future results of operations and financial position,
our strategic and financial initiatives, our business strategy and
plans and our objectives for future operations, are forward-looking
statements. Such forward-looking statements, including statements
regarding clinical trials, clinical studies and other clinical work
(including the funding therefor, anticipated patient enrollment,
safety data, study data, trial outcomes, timing or associated
costs), regulatory applications and related anticipated submission
contents and timelines, including potential resubmission of
the New Drug Application (NDA) following our receipt of a Complete
Response Letter (CRL) in November 2020, the potential for eventual
U.S. Food and Drug Administration (FDA) approval of the NDA
for LIQ861, the timeline or outcome related to our patent
litigation pending in the U.S. District Court for the District
of Delaware or its inter partes review with the
Patent Trial and Appeal Board (PTAB), the issuance of patents by
the U.S. Patent and Trademark Office (USPTO) and our ability to
execute on our strategic or financial initiatives, involve
significant risks and uncertainties and actual results could differ
materially from those expressed or implied herein. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “would,” and similar expressions are intended
to identify forward-looking statements. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy, short-term and long-term business operations and
objectives and financial needs. These forward-looking statements
are subject to a number of risks discussed in Liquidia’s filings
with the SEC, including the impact of the coronavirus
(COVID-19) outbreak on our company and our financial condition and
results of operations, the ability of Liquidia and RareGen to
integrate their businesses successfully and to achieve anticipated
cost savings and other synergies, the possibility that other
anticipated benefits of the completed merger transaction between
Liquidia and RareGen will not be realized, including without
limitation, anticipated revenues, expenses, earnings and other
financial results, and growth and expansion of the new combined
company’s operations, and the anticipated tax treatment, as well as
a number of uncertainties and assumptions. Moreover, we operate in
a very competitive and rapidly changing environment and our
industry has inherent risks. New risks emerge from time to time. It
is not possible for our management to predict all risks, nor can we
assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements we may make. In light of these risks,
uncertainties and assumptions, the future events discussed in this
press release may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. Nothing in this press release should be
regarded as a representation by any person that these goals will be
achieved, and we undertake no duty to update our goals or to update
or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact
InformationMedia:Michael ParksCorporate
Communications484.356.7105michael.parks@liquidia.com
Investors:Jason AdairVice President, Corporate
Development and Strategy919.328.4400jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Sep 2023 to Sep 2024